- Home
- ELVN vs HROW Comparison
ELVN vs HROW Comparison
Compare ELVN & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- HROW
- Stock Information
- Founded
- ELVN 2016
- HROW 1998
- Country
- ELVN United States
- HROW United States
- Employees
- ELVN N/A
- HROW N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- HROW Biotechnology: Pharmaceutical Preparations
- Sector
- ELVN Health Care
- HROW Health Care
- Exchange
- ELVN Nasdaq
- HROW Nasdaq
- Market Cap
- ELVN 927.8M
- HROW 1.1B
- IPO Year
- ELVN 2020
- HROW N/A
- Fundamental
- Price
- ELVN $21.30
- HROW $30.66
- Analyst Decision
- ELVN Strong Buy
- HROW Strong Buy
- Analyst Count
- ELVN 5
- HROW 6
- Target Price
- ELVN $39.60
- HROW $59.00
- AVG Volume (30 Days)
- ELVN 594.3K
- HROW 433.0K
- Earning Date
- ELVN 08-12-2025
- HROW 08-06-2025
- Dividend Yield
- ELVN N/A
- HROW N/A
- EPS Growth
- ELVN N/A
- HROW N/A
- EPS
- ELVN N/A
- HROW N/A
- Revenue
- ELVN N/A
- HROW $212,858,000.00
- Revenue This Year
- ELVN N/A
- HROW $44.92
- Revenue Next Year
- ELVN N/A
- HROW $38.12
- P/E Ratio
- ELVN N/A
- HROW N/A
- Revenue Growth
- ELVN N/A
- HROW 53.49
- 52 Week Low
- ELVN $13.30
- HROW $19.31
- 52 Week High
- ELVN $30.03
- HROW $59.23
- Technical
- Relative Strength Index (RSI)
- ELVN 55.53
- HROW 57.58
- Support Level
- ELVN $18.53
- HROW $30.01
- Resistance Level
- ELVN $24.11
- HROW $31.63
- Average True Range (ATR)
- ELVN 1.96
- HROW 1.59
- MACD
- ELVN 0.15
- HROW 0.02
- Stochastic Oscillator
- ELVN 55.68
- HROW 66.10
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
About HROW Harrow Inc.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.